Clinical Trial Update: A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib [Phase 2]

View source ↗

Summary

Phase 2 trial updating colon pathology in patients with HER2-amplified breast cancer treated with neratinib has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• neratinib (neratinib)

Snippet

Sponsor: Puma Biotechnology, Inc. | Conditions: HER2 Amplified Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2023-02-10